Multicenter trial of fluocinonide in an emollient cream base.
Working independently, eight investigators evaluated the clinical effectiveness of fluocinonide 0.05% in a three-week double-blind paired comparison trial of 240 patients. Half the investigators compared fluocinonide emollient cream with betamethasone valerate 0.1% cream in the treatment of atopic dermatitis, while the remaining four compared the study drug with triamcinolone acetonide 0.1% cream in the treatment of psoriasis. Statistical analysis showed clinical responses favored fluocinonide p = 0.021 (Wilcoxon Signed Rank) for the atopic dermatitis group and p = 0.001 (Wilcoxon Signed Rank) for the psoriasis group.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001624:Betamethasone Valerate / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D005446:Fluocinolone Acetonide / Q000031:analogs & derivatives*; D005447:Fluocinonide / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009824:Ointments; D011565:Psoriasis / Q000188:drug therapy*; D014222:Triamcinolone Acetonide / Q000627:therapeutic use
D009824:Ointments; D005446:Fluocinolone Acetonide; D005447:Fluocinonide; D001624:Betamethasone Valerate; D014222:Triamcinolone Acetonide